Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data

Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.

Authors

Institutions

Publication Details

Journal
Hematological Oncology
Published
2025-01-01
DOI
https://doi.org/10.1002/hon.70024
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data

Marc Sorigué, Aino Rajamäki, Outi Kuittinen, Arja Jukkola‐Vuorinen et al.
3 links
Hematological Oncology
Lymphoma Diagnosis and Treatment
article

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data

Marc Sorigué, Aino Rajamäki, Outi Kuittinen, Arja Jukkola‐Vuorinen, Aino Rönkä, Kaisa Sunela, Roosa Prusila, Tuula Klaavuniemi, Reijo Sund, Erika Alanne, Mika Hujo, Hanne Kuitunen, Juan‐Manuel Sancho, Esa Kari, Minna Harmanen, Esa Jantunen, Madiha Khan
article en

Abstract

Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.

Hematological OncologyVol. 43(1)
University of Eastern Finland (FI), Oulu University Hospital (FI), Turku University Hospital (FI), Kuopio University Hospital (FI), Tampere University Hospital (FI), Tampere University (FI), Hospital Universitari Germans Trias i Pujol (ES), University of Oulu (FI)
Good health and well-being
Openalex Percentile: Top 100%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.